CL2023001462A1 - Anticuerpos ampliamente neutralizantes contra la neuraminidasa de influenza - Google Patents

Anticuerpos ampliamente neutralizantes contra la neuraminidasa de influenza

Info

Publication number
CL2023001462A1
CL2023001462A1 CL2023001462A CL2023001462A CL2023001462A1 CL 2023001462 A1 CL2023001462 A1 CL 2023001462A1 CL 2023001462 A CL2023001462 A CL 2023001462A CL 2023001462 A CL2023001462 A CL 2023001462A CL 2023001462 A1 CL2023001462 A1 CL 2023001462A1
Authority
CL
Chile
Prior art keywords
antibodies against
neutralizing antibodies
against influenza
broadly neutralizing
influenza neuraminidase
Prior art date
Application number
CL2023001462A
Other languages
English (en)
Spanish (es)
Inventor
Cameroni Elisabetta
Snell Gyorgy
Corti Davide
Samuele Pizzuto Matteo
Minola Andrea
Ferri Elena
Original Assignee
Vir Biotechnology Inc
Humabs Biomed Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vir Biotechnology Inc, Humabs Biomed Sa filed Critical Vir Biotechnology Inc
Publication of CL2023001462A1 publication Critical patent/CL2023001462A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CL2023001462A 2020-11-23 2023-05-22 Anticuerpos ampliamente neutralizantes contra la neuraminidasa de influenza CL2023001462A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063117448P 2020-11-23 2020-11-23
US202063123424P 2020-12-09 2020-12-09
US202163197160P 2021-06-04 2021-06-04
US202163261463P 2021-09-21 2021-09-21

Publications (1)

Publication Number Publication Date
CL2023001462A1 true CL2023001462A1 (es) 2023-10-20

Family

ID=79021106

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023001462A CL2023001462A1 (es) 2020-11-23 2023-05-22 Anticuerpos ampliamente neutralizantes contra la neuraminidasa de influenza

Country Status (13)

Country Link
US (1) US20240092876A1 (enExample)
EP (1) EP4247495A1 (enExample)
JP (1) JP2023551668A (enExample)
KR (1) KR20230137293A (enExample)
AU (1) AU2021381778A1 (enExample)
CA (1) CA3199023A1 (enExample)
CL (1) CL2023001462A1 (enExample)
CO (1) CO2023007527A2 (enExample)
IL (1) IL302963A (enExample)
MX (1) MX2023005654A (enExample)
PH (1) PH12023551390A1 (enExample)
TW (1) TW202229329A (enExample)
WO (1) WO2022109309A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260184814A1 (en) * 2022-05-23 2026-07-02 Humabs Biomed Sa Broadly neutralizing antibodies against influenza neuraminidase
AU2023358546A1 (en) * 2022-10-14 2025-05-29 Longhorn Vaccines And Diagnostics, Llc Vaccines and antibodies for the treatment and prevention of microbial infections
WO2026021428A1 (en) * 2024-07-23 2026-01-29 Westlake University Anti-neuraminidase antibodies and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7803C (enExample)
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
WO2005028515A1 (ja) 2003-09-24 2005-03-31 Kyowa Hakko Kogyo Co., Ltd. ヒトインスリン様成長因子に対する遺伝子組換え抗体
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2008042814A2 (en) 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
AU2014374055B2 (en) 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
US10072070B2 (en) * 2014-12-05 2018-09-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Potent anti-influenza A neuraminidase subtype N1 antibody
US11267899B2 (en) 2015-05-13 2022-03-08 Zumutor Biologics Inc. Afucosylated protein, cell expressing said protein and associated methods
WO2018187706A2 (en) * 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
WO2019024979A1 (en) 2017-07-31 2019-02-07 Institute For Research In Biomedicine FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION
CN117843810A (zh) 2017-09-22 2024-04-09 上海药明生物技术有限公司 新型双特异性多肽复合物
CA3096703A1 (en) * 2018-05-03 2019-11-07 University Of Rochester Anti-influenza neuraminidase monoclonal antibodies and uses thereof

Also Published As

Publication number Publication date
AU2021381778A9 (en) 2025-01-09
KR20230137293A (ko) 2023-10-04
JP2023551668A (ja) 2023-12-12
CA3199023A1 (en) 2022-05-27
WO2022109309A9 (en) 2022-09-01
US20240092876A1 (en) 2024-03-21
TW202229329A (zh) 2022-08-01
PH12023551390A1 (en) 2023-12-04
WO2022109309A1 (en) 2022-05-27
MX2023005654A (es) 2023-07-31
IL302963A (en) 2023-07-01
EP4247495A1 (en) 2023-09-27
CO2023007527A2 (es) 2023-08-18
AU2021381778A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
CO2022013525A2 (es) Anticuerpos contra sars-cov-2 y métodos para usarlos
DOP2021000026A (es) Anticuerpos que se unen específicamente a los epítopos del virus del zika y usos de los mismos
CL2024002250A1 (es) Uso de anticuerpo anti-vd1 para tratar cáncer, una enfermedad infecciosa o una enfermedad inflamatoria.
CO2023007527A2 (es) Anticuerpos ampliamente neutralizantes contra neuraminidasa de influenza
CO2020004199A2 (es) Anticuerpos específicos cd47/pd-l1
CO2017006580A2 (es) Anticuerpos humanos para hemaglutinina de influenza
MX2021002690A (es) Anticuerpos anti-avb8 y composiciones y usos de los mismos.
CL2023003695A1 (es) Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, métodos de uso
WO2018187706A3 (en) Anti-influenza b virus neuraminidase antibodies and uses thereof
CL2021002807A1 (es) Anticuerpos y métodos para el tratamiento de la infección por influenza a
CL2024000091A1 (es) Anticuerpos y fragmentos de unión al antígeno antiglicoproteína de la espícula de sars-cov-2
CL2020001884A1 (es) Anticuerpos humanos para la hemaglutinina de influenza.
UY36820A (es) Anticuerpos monoclonales específicos para el antígeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por vrsh
CO2021008774A2 (es) Anticuerpos monoclonales específicos para el antígeno pb2 del virus de la influenza humana (flu), secuencias nucleotídicas; método y kit de diagnóstico de infección producida por flu
CL2022002404A1 (es) Anticuerpos anti-gitr y usos de estos
CO2022005281A2 (es) Anticuerpos antihemaglutinina y métodos de uso de estos
AR124118A1 (es) Anticuerpos ampliamente neutralizantes contra la neuraminidasa de influenza
AR130046A1 (es) Anticuerpos ampliamente neutralizantes contra los paramixovirus vsr y mpv
CO2025006994A2 (es) Anticuerpos anti–cd137 y métodos de uso
CL2023000221A1 (es) Anticuerpos y métodos para el tratamiento de la infección por influenza a
AR119296A1 (es) Anticuerpos de glicoproteína anti proteína s de sars cov-2- y fragmentos de unión de antígenos
AR118787A1 (es) Moléculas de unión a pd-l1 y uso de las mismas para el tratamiento de enfermedades